Projected Impact of Omidubicel-onlv on Racial/Ethnic Disparities in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Outcomes in Hematologic Malignancies.

Saved in:
Bibliographic Details
Title: Projected Impact of Omidubicel-onlv on Racial/Ethnic Disparities in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Outcomes in Hematologic Malignancies.
Authors: Khera N; Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA., Edwards ML; Analysis Group Inc., New York, NY, USA., Song Y; Analysis Group Inc., Boston, MA, USA., Sun R; Analysis Group Inc., Boston, MA, USA., Manghani R; Gamida Cell Inc., Boston, MA, USA., Shin H; Gamida Cell Inc., Boston, MA, USA., Simantov R; Gamida Cell Inc., Boston, MA, USA., Signorovitch J; Analysis Group Inc., Boston, MA, USA., Sivaraman S; Gamida Cell Inc., Boston, MA, USA., Gergis U; Department of Medical Oncology, Thomas Jefferson University, 834 Chestnut St, Ste 308, Philadelphia, PA, 19107, USA. usama.gergis@jefferson.edu.
Source: Advances in therapy [Adv Ther] 2024 Apr; Vol. 41 (4), pp. 1637-1651. Date of Electronic Publication: 2024 Mar 01.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Be the first to leave a comment!
You must be logged in first